First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) plus /- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

被引：9
|
作者：
Miles, D. [1 ]
Cameron, D. [2 ,3 ]
Bondarenko, I. [4 ]
Lyudmila, M. [5 ]
Alcedo, J. C. [6 ]
Lopez, R. I. [7 ,8 ]
Im, S. A. [9 ]
Canon, J. L. [10 ]
Shparyk, Y. [11 ]
Yardley, D. [12 ,13 ]
Masuda, N. [14 ]
Ro, J. [15 ]
Hubeaux, S. [16 ]
Quah, C. [17 ]
Bais, C. [17 ]
O'Shaughnessy, J. [18 ,19 ]
机构：
[1] Mt Vernon Canc Ctr, Med Oncol, Northwood, Middx, England
[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[3] NHS Lothian, Canc Serv, Med Oncol, Edinburgh, Midlothian, Scotland
[4] Dnepropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnepropetrovsk, Ukraine
[5] NN Blokhin Canc Ctr, Med Oncol, Moscow, Russia
[6] Ctr Hemato Oncol Paitilla, Med Oncol, Panama City, Panama
[7] Natl Oncol Inst, Panama City, Panama
[8] Ctr Oncol Punta Pacifica, Med Oncol, Panama City, Panama
[9] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[10] Grand Hop Charleroi, Oncol & Haematol, Charleroi, Belgium
[11] Lviv State Oncol Reg Treatment & Diagnost Ctr, Med Oncol, Lvov, Ukraine
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Med Oncol, Nashville, TN USA
[14] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan
[15] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea
[16] F Hoffmann La Roche Ltd, Biostat, Pharma Dev, Basel, Switzerland
[17] Genentech Inc, Global Dev BioOncol, San Francisco, CA 94080 USA
[18] Baylor Charles A Sammons Canc Ctr, US Oncol, Dallas, TX USA
[19] Texas Oncol, Med Oncol, Dallas, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30816-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1866
引用
收藏
页码：S287 / S288
页数：2
相关论文
共 50 条
  • [21] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] FIRST EFFICACY RESULTS FROM THE TURANDOT PHASE III TRIAL COMPARING TWO BEVACIZUMAB (BEV)-CONTAINING REGIMENS AS FIRST-LINE THERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Zielinski, C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
  • [23] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
  • [24] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [25] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [26] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [27] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
  • [28] Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study
    Schrader, Iris
    Foerster, Frank Gerhard
    Schneeweiss, Andreas
    Geberth, Matthias
    Hahn, Lars
    Schumacher, Claudia
    Hertz-Eichenrode, Martin Michael
    Schoenegg, Winfried
    Wolfgarten, Matthias Kim
    Kutscheidt, Andreas
    Schmidt, Marcus
    Aktas, Bahriye
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial
    Schmid, Peter
    Abraham, Jacinta
    Chan, Stephen
    Wheatley, Duncan
    Brunt, Murray
    Nemsadze, Gia
    Baird, Richard
    Park, Yeon Hee
    Hall, Peter
    Perren, Timothy
    Stein, Robert C.
    Laszlo, Mangel
    Ferrero, Jean-Marc
    Phillips, Melissa
    Conibear, John
    Sarker, Shah-Jalal
    Prendergast, Aaron
    Cartwrightx, Hayley
    Mousa, Kelly
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
    Dent, R.
    Oliveira, M.
    Isakoff, S. J.
    Im, S-A.
    Espie, M.
    Blau, S.
    Tan, A. R.
    Saura, C.
    Wongchenko, M.
    Xu, N.
    Bradley, D.
    Reilly, S-J.
    Mani, A.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2020, 31 : S64 - S65
12345